Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bleomycin pulmonary toxicity: current status and future directions.

R L Comis1

  • 1Medical Science Division, Fox Chase Cancer Center, Philadelphia, PA 19111.

Seminars in Oncology
|April 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Future directions in the treatment of non-small cell lung cancer.

Seminars in oncology·2000
Same author

The role of oral etoposide in non-small cell lung cancer.

Drugs·2000
Same author

The Cooperative Groups: past and future.

Cancer chemotherapy and pharmacology·1998
Same author

Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors.

Cancer·1998
Same author

Small-cell lung cancer: a perspective on the past and a preview of the future.

Oncology (Williston Park, N.Y.)·1998

Bleomycin is a chemotherapy drug with known pulmonary toxicity risks. Monitoring lung function with tests like DLCO can help ensure safe administration and patient outcomes.

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Bleomycin is a widely used polypeptide antibiotic in cancer chemotherapy.
  • Significant pulmonary toxicity is a major concern with bleomycin treatment.
  • Risk factors include dosage, patient age, oxygen therapy, and radiation exposure.

Purpose of the Study:

  • To review the risk factors and monitoring strategies for bleomycin-induced pulmonary toxicity.
  • To discuss advancements in understanding the pathogenesis of bleomycin lung injury.
  • To highlight the development of less toxic bleomycin analogues.

Main Methods:

  • Literature review of clinical studies and research on bleomycin toxicity.
  • Analysis of risk factors and current monitoring techniques.

Related Experiment Videos

  • Examination of emerging research on bleomycin analogues and toxicity mechanisms.

    • Main Results:

    • Clinical and laboratory tests, including the Diffusing capacity of the lungs for carbon monoxide (DLCO) test, aid in safe bleomycin administration.
    • Predictive and precise monitoring systems for bleomycin pulmonary toxicity remain challenging.
    • New analogues like liblomycin show potential for reduced pulmonary toxicity.

    Conclusions:

    • Safe administration of bleomycin requires careful consideration of risk factors and monitoring.
    • Further research into the immune system's role in bleomycin lung injury is crucial.
    • Development of safer bleomycin analogues is a promising area for future cancer therapy.